Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFF332 in advanced ccRCC and HIF2α-stabilizing malignancies
NCT04895748Phase 1Terminated
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Feb 2026
- Countries
- 7
01
Overview
Phase 1, open-label trial of DFF332 in clear cell renal cell carcinoma (ccRCC), von Hippel–Lindau disease (VHL), Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) and 2 more, sponsored by Novartis. Primary endpoints: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) at 3 years, Number of participants with dose interruptions and dose reductions at 3 years and 2 more. Started Nov 2021; status: terminated.
02
Drugs
DFF332
03
Conditions
clear cell renal cell carcinoma (ccRCC)von Hippel–Lindau disease (VHL)Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)hereditary paraganglioma and pheochromocytoma syndrome (PGL/PCC)malignant neoplasm
Beyond the preview
Go deeper on NCT04895748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895748.